United States · Bill · HR
H.R. 3761 (117th)
Promising Pathway Act
Introduced
8 June 2021
Last action
9 June 2021 · Referred
Status
Referred to the Subcommittee on Health.
Sponsors
Rep. Gallagher, Mike [R-WI-8], Rep. Quigley, Mike [D-IL-5], Rep. Westerman, Bruce [R-AR-4], Rep. Swalwell, Eric [D-CA-15], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Auchincloss, Jake [D-MA-4], Rep. Hartzler, Vicky [R-MO-4], Rep. McGovern, James P. [D-MA-2], Anthony Gonzalez, Rep. Trahan, Lori [D-MA-3]
Subjects
Healthcare
Source updated
5 December 2025
Summary
Promising Pathway Act This bill establishes a provisional approval pathway for medicines intended for serious or life-threatening diseases, including illnesses posing a threat of epidemic or pandemic. The period of the provisional approval is for two years and is potentially renewable. The Food and Drug Administration (FDA) must establish a priority review system to evaluate completed provisional approval applications within 90 days of receipt. A provisional approval application may be approved if the FDA determines that (1) there is substantial evidence of safety for the drug; and (2) there is relevant early evidence of efficacy, based on adequate and well-controlled investigations. During the COVID-19 (i.e., coronavirus disease 2019) pandemic, or another epidemic or pandemic, the FDA must accept and review various portions of a provisional approval application on a rolling basis. The manufacturer of a provisionally approved drug must require patients to participate in an observational registry. A manufacturer that fails to comply with registry requirements is subject to civil penalties. A provisionally approved drug must be labeled as such. If a drug that receives provisional approval status is not brought to market within 180 days of the approval, the approval must be rescinded. The bill also limits the liability of a manufacturer of a provisionally approved drug with respect to any claim under state law alleging that the drug is unsafe or ineffective. Private health insurers and federal health care programs shall not deny coverage of a provisionally approved drug on the basis of it being experimental.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
8 June 2021
Introduced
Referred to the House Committee on Energy and Commerce.
Source: IntroReferral
8 June 2021
Introduced
Introduced in House
Source: IntroReferral
8 June 2021
Introduced
Introduced in House
Source: IntroReferral
9 June 2021
Referred
Referred to the Subcommittee on Health.
Source: Committee
Votes
No vote records are attached yet.
Versions
- Introduced in House · 8 June 2021 · Download file
Documents
3 official files
Introduced in House (text)
This file cannot be previewed here. Use View or Download.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House (text)
Introduced in House · EN · 8 June 2021
Introduced in House (PDF)
Introduced in House · EN · 8 June 2021
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House
summary · EN · 8 June 2021
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- Rep. Gallagher, Mike [R-WI-8] · R · Sponsor
- Rep. Quigley, Mike [D-IL-5] · D · Sponsor
- Rep. Westerman, Bruce [R-AR-4] · R · Sponsor
- Rep. Swalwell, Eric [D-CA-15] · D · Sponsor
- Rep. Fitzpatrick, Brian K. [R-PA-1] · R · Cosponsor
- Rep. Auchincloss, Jake [D-MA-4] · D · Cosponsor
- Rep. Hartzler, Vicky [R-MO-4] · R · Cosponsor
- Rep. McGovern, James P. [D-MA-2] · D · Cosponsor
- Anthony Gonzalez · R · Cosponsor
- Rep. Trahan, Lori [D-MA-3] · D · Cosponsor
- · hsif00 · Standing
Related records
- related to → Promising Pathway Act
- related to ← Fair Care Act of 2022
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/house-bill/3761
- Open data entity: https://api.congress.gov/v3/bill/117/hr/3761
- us · 117-hr-3761 · source updated 5 December 2025